Analysis of Antihypertensive Treatment Efficacy (ATACA)
Sponsor: AstraZeneca
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from AstraZeneca
Other Arterial Hypertension trials with similar outcome
This observational or N/A phase trial investigates Arterial Hypertension and is currently terminated or withdrawn. AstraZeneca leads this study, which shows 7 recorded versions since 2008 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated
-
Sep 2024 — Sep 2025 [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jan 2021 — Jul 2024 [monthly]
Terminated
-
Jun 2018 — Jan 2021 [monthly]
Terminated
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Terminated
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Terminated NA
First recorded
May 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Arhangelsk, Russia , Bryansk, Russia , Domodedovo, Russia , Dzerzhinsk, Russia , Georgiyevsk, Russia , Irkutsk, Russia , Kazan', Russia , Samara, Russia , Severodvinsk, Russia , Vidnoye, Russia and 3 more locations